Quantcast
Home / Practice Areas / Personal Injury and Tort / First Neurontin trial begins

First Neurontin trial begins

Plaintiffs’ lawyer attacks off-label marketing

BOSTON - Addressing jurors in the first Neurontin suicide trial, plaintiffs' lawyer Mark Lanier asserted that drug maker Pfizer knew the anti-epilepsy medication increased the risk of suicide, but intentionally marketed off-label uses to boost the drug's sales.